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Abstract 
This review addresses what is new in 
functional and motility disorders in the lower 
gastrointestinal tract: biomarkers and actionable 
biomarkers in irritable bowel syndrome (IBS), 
dietary and pharmacological treatment of abdominal 
pain in IBS, how to screen for rectal evacuation 
disorders in chronic constipation, hypotheses on the 
etiology of infantile colic, and lessons learned from 
the appraisal of an esoteric colonic motor disorder, 
that is, megacolon in association with multiple 
endocrine neoplasia type 2B. Understanding the 
mechanisms has moved these from idiopathic or 
cryptogenic disorders to organic diseases and has 
changed the attitude of health care providers to 
empathize with the suffering and legitimate pleas of 
millions of patients for effective therapies. 
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Introduction 
Irritable bowel syndrome (IBS) is generally 
diagnosed based on symptoms of persistent 
abdominal pain that is associated with diarrhea 
(IBS-D), constipation (IBS-C), or both (IBS-M).1 
The diagnosis should rely on the clinical history so 
that invasive and expensive testing can be avoided. 
However, the diagnosis of IBS may not be easy and 
may involve multiple clinic and emergency room 
visits, extensive investigations including blood and 
fecal tests, and multiple radiographic and 
endoscopic studies to exclude inflammatory bowel 
diseases (IBD), celiac disease, and gastrointestinal 
infections. There have been significant advances in 
the understanding of motility and functional lower 
gastrointestinal disorders that augur well for 
optimizing management of patients with these 
conditions. 
There is considerable evidence of abnormal 
peripheral mechanisms in IBS.2 These mechanisms 
can be identified, in part, through biomarkers which 
are molecular, histologic, radiographic or 
physiologic characteristics that indicate a normal 
biological or pathological process or responses to 
therapeutic or non-therapeutic interventions.3  
Mechanisms and Biomarkers of IBS 
An ideal biomarker measures a biological 
substance, structure or process that influences the 
outcome of a disease, even though few biomarkers 
actually qualify as surrogate or clinical endpoints.4 
Several biomarkers have been proposed in 
IBS [Figure 1], including fecal, blood, mucosal, 
microbial, radiological (including brain imaging), 
and genetic markers. IBS biomarkers’ clinical 
utility greatly depends on our understanding of their 
functions in normal physiology and in the 
pathophysiology of IBS. A clinically useful 
biomarker needs to be safe, easy to measure, cost 
effective and actionable. The term “actionable” 
biomarker reflects the fact that the biomarker is 
helpful for the subclassification of diseases and 
directly impacts the selection of therapy. Validated 
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biomarkers may, in the future, potentially replace 
symptom-based criteria for IBS and aid in 
accurately identifying subgroups of patients beyond 
the symptom-based classifications, that is, bowel 
dysfunction and the presence or absence of 
significant pain. 
 
 
Figure 1:  Biomarkers in IBS. Reproduced with permission from ref. 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody panels 
Antibodies to cytolethal distending toxin B 
(cdtB) (a toxin produced by C. jejuni) and Viniculin 
(component of adherens junction proteins) have 
been proposed for differentiating IBS-D from IBD 
and health.5 However, anti-CdtB antibody was also 
elevated in patients with celiac disease, an 
important diagnosis to be differentiated in patients 
with suspected IBS-D. This test is now 
commercially available as IBSchek. 
A panel of 10 markers, consisting 
predominantly of antibodies or inhibitors to 
endogenous proteins or bacteria and 
neurotransmitters, was used to differentiate IBS 
from IBD, celiac disease and functional disorders. 
However, the sensitivity was only 50%.6 In 
addition, some of the biomarkers used in that 
analysis were not specific to IBS, and, thus, the test 
was not able to differentiate between the different 
subclasses of IBS. In another study, a different 
panel used 8 predominantly inflammatory 
biomarkers with a sensitivity of 88.1% and 
specificity of 86.5% to differentiate patients with 
IBS from healthy controls.7 Differentiation from 
other diseases mimicking IBS with this panel 
requires further study.  
Further validation of these markers or panels 
in more diverse groups will help clarify their 
generalizability for application as diagnostic tests.  
 
Bile acids 
In clinical practice in the United States, 
quantifying fecal bile acids using a 48-hour stool 
collection is the gold standard test for bile acid 
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malabsorption. Other tests for detection of bile acid 
malabsorption (BAM) are used in other countries; 
these include 75Se-homocholic acid taurine 
(SeHCAT) retention test. Screening blood tests in 
development are fasting serum FGF-19, a regulator 
of hepatic bile acid synthesis which is low in 
BAM,8 and fasting serum 7α-hydroxy-4-cholesten-
3-one (C4).9
Several meta-analyses based on clinical 
studies have demonstrated that approximately 30% 
of patients with IBS-D has evidence of BAM.10-12 
Deoxycholic acid (DCA) and chenodeoxycholic 
acid (CDCA) were lower in IBS-C patients 
compared to healthy volunteers.13   
Colesevelam, a bile acid sequestrant, 
sequestered intraluminal bile acids and increased 
stool consistency in IBS-D patients.14 In the future, 
ileal bile acid transporter inhibitors such as 
elobixibat may be available for patients with 
constipation.  
Calprotectin 
Calprotectin is a neutrophil-derived protein 
found in the cytosol of neutrophils; it acts as a 
biomarker for inflammation. Elevated fecal 
calprotectin helps differentiate patients with active 
inflammatory colitis such as IBD15 from those with 
microscopic colitis.16 Several studies in IBS 
patients have demonstrated similar fecal 
calprotectin levels compared to healthy controls17 
and patients with IBD in deep remission.15  
A meta-analysis of 8 studies with 565 patients 
with IBD, 259 with IBS, and 238 healthy controls 
demonstrated that there was no level of fecal 
calprotectin that could completely exclude IBS.  
Fecal calprotectin helps exclude IBD at a level 
<40 µg/g stool, but it is not a reliable biomarker for 
IBS. If IBD is excluded by imaging (e.g., 
colonoscopy), a high fecal calprotectin level may 
identify patients with immune activation as a 
component of the IBS mechanism.  
GI motility measurements 
Multiple tests are now available to evaluate 
gastrointestinal motility, including radiopaque 
marker studies, scintigraphy, and the wireless 
motility capsule.18-19 In a study of 287 patients with 
lower functional gastrointestinal disorders, 
approximately 30% had abnormal colonic transit by 
scintigraphy: delayed transit in 22.9% of patients 
with IBS-C and functional constipation, and 
accelerated transit in 33.3% of patients with IBS-D 
and functional diarrhea. Discordant results were 
rare: 4.5% of patients with IBS-D or functional 
diarrhea had delayed transit at 48 hours, and 4.2% 
of IBS-C or functional constipation patients had 
accelerated transit at 24 hours.20 
Abnormal colonic transit, measured by 
scintigraphy, was associated with symptoms 
including stool consistency, frequency of bowel 
movements, and ease of passage of stool.21 Colonic 
transit was an independent predictor of IBS 
compared to healthy volunteers, with well-
established normal values (GC 24 of 1.3–4.4; GC48 
1.9–5.0).22  Additionally, colonic transit with 
geometric center at 48 hours is an independent 
predictor in discriminating healthy individuals from 
IBS-C patients, and IBS-C patients from IBS-D 
patients,23 but it does not discriminate between slow 
transit due to colonic dysmotility and constipation 
due to rectal evacuation disorders.24 
Psychological traits 
Psychological assessment has been used as a 
marker of illness in IBS. Psychological measures, 
such as the Hospital Anxiety and Depression scale, 
the Patient Health Questionnaire and the Perceived 
Stress Scale, have been added to enhance the ability 
of the IBS biomarker panels to differentiate IBS 
cases from healthy volunteers.25  
On the other hand, psychological markers 
used alone are likely not sufficient to identify bowel 
disturbances or their severity in IBS, but they may 
be more closely associated with the pain/discomfort 
in IBS.  
Actionable biomarkers in IBS 
Individually, symptom-based diagnostic 
criteria performed modestly in the prediction of 
IBS,26 and the diagnostic performance of symptom-
based criteria is enhanced by additional history 
(e.g., nocturnal stools, somatization) and limited 
diagnostic tests (e.g., hemoglobin and C-reactive 
protein levels).27  
A systematic review of biomarkers has 
appraised diverse markers.28 Overall, the most 
promising biomarkers with the greatest actionability 
are colonic transit and bile acid secretion, as they 
can be measured by several methods that are 
applicable in clinical practice. Additionally, there 
are specific efficacious therapies directed at 
reversing the pathophysiological mechanisms 
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identified by those biomarkers. 
Dietary and Pharmacological Treatment of 
Abdominal Pain in Irritable Bowel Syndrome  
Abdominal pain remains the greatest unmet 
need in the treatment of IBS. A recent article29 
appraised the available literature on dietary, 
probiotics and pharmacotherapy of pain in IBS, and 
a summary of efficacy is provided in Table 1. The 
main approaches to treatment remain 
antispasmodics and antidepressants, and it is hoped 
that advances in neurobiology of pain or further 
understanding of the microbiome might lead to 
novel approaches to therapy that remain 
experimental even for drugs that are used off-label, 
such as non-sedating anti-histamines and GABA-
ergic agents.   
Table 1:  Efficacy of interventions on the relief of symptoms in IBS: Relative risk (RR) or odds ratio (OR) and 
confidence interval (CI) based on systematic reviews and meta-analyses. Reproduced with permission from ref. 
29 
Intervention Parameter RR or OR Ref. # 
Dietary or Probiotics or Antibiotics 
Bran, ispaghula and unspecified 
fiber  
Abdominal pain RR 0.87 (0.76-1.00) 49 
Low FODMAP diet Abdominal pain OR 1.81 (1.13-2.88) 50 
Probiotics Global improvement SEM: -0.25 (-0.36,  -0.14) 51 
Probiotics: combination of E. coli 
+ Enterococcus faecalis OR
E. coli alone
Abdominal pain RR 1.96 (1.14-3.36) 52,53 
Rifaximin 
Rifaximin 
Global improvement OR 1.57 (1.22-2.01) 54 
Bloating OR 1.55 (1.23-1.96) 54 
Antispasmodics 
Peppermint oil Global improvement RR 2.23 (1.78-2.81) 55 
Antidepressants 
Antidepressant therapy Global improvement RR 0.66 (0.57-0.78) 56 
Abdominal pain RR 0.62 (0.43-0.88) 56 
Antidepressant therapy Global improvement RR 0.67 (0.58-0.77) 57,58 
Antidepressant therapy Abdominal pain RR 0.62 (0.43-0.88) 57,58 
Drugs Targeting Specific Gastrointestinal Receptors 
Alosetron Abdominal pain and 
discomfort 
RR 1.30 (1.22-1.39) 59 
Overall risk 
difference 
0.13 (0.1-0.16) 59 
Alosetron Abdominal pain and 
discomfort 
RR 1.23 (1.15-1.32) 60 
Global improvement RR 1.5 (1.40-1.72) 60 
Ondansetron Adequate relief 
response 
RR 4.7 (2.6-8.5) 61 
Linaclotide Adequate relief 
response 
RR1.95 (1.3-2.9) 62 
Abdominal pain RR 1.58 (1.02-2.46) 62 
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Chronic Diarrhea 
Algorithm for evaluation of chronic diarrhea 
Figure 2 shows a proposed algorithm for the 
diagnosis of chronic diarrhea.30   
It is important to appraise the presence of 
rectal bleeding, features of malabsorption, or 
symptoms of IBS from the patients’ histories. If 
there are no rectal blood or features of 
malabsorption, a limited screen for organic disease 
may include hematology and chemical analyses, 
and tests to measure C-reactive protein, erythrocyte 
sedimentation rate, serum iron, folate, vitamin B12, 
tissue transglutaminase-IgA (to detect celiac 
disease), serum level of 7α-hydroxy-4-cholesten-3-
one or fibroblast growth factor 19 (if available, to 
detect bile acid diarrhea), and examinations for 
excess fat or calprotectin in a random stool sample. 
In addition, colonoscopy and biopsy are usually 
performed according to recommendations for 
colorectal cancer screening, or in patients with 
intractable watery diarrhea to exclude microscopic 
colitis. American Gastroenterological Association 
guidelines specify the importance of excluding 
celiac disease, hyperthyroidism, IBS, and 
medication use (e.g. non-steroidal anti-
inflammatory drugs, aspirin, proton-pump 
inhibitors, clozapine, and acarbose) when 
considering the possibility of microscopic colitis.31 
Figure 2: Algorithm for management of chronic diarrhea. Patients undergo an initial evaluation based on 
different symptom presentations, leading to selection of patients for imaging, biopsy analysis, and limited 
screens for organic diseases. Reproduced with permission from ref. 30 
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The next steps in the management algorithm 
are guided by results of the initial screen for organic 
disease.  The next steps include further specific tests 
when features indicate IBD or malabsorption. When 
results from all tests are normal and suggest chronic 
watery diarrhea typically without hypokalemia, 
opioid therapy should be tested (e.g. loperamide, 2– 
4 mg, as many as 4 times/day), with preprandial 
dosing for patients with prominent postprandial 
diarrhea. If the diarrhea persists, patients should be 
formally tested for bile acid malabsorption or given 
a trial of bile acid sequestrants if the tests for BAM 
are unavailable (e.g. 48h total fecal BA, or 
75SeHCAT retention at 7 days; measurement of 
colonic transit will make it easier to select 
subsequent therapies. Tests for small intestinal 
bacterial overgrowth (SIBO- still best achieved by 
small bowel aspirates and culture) should be 
considered when there is evidence of malabsorption 
from the screening tests for organic disease, such as 
hypoalbuminemia or positive qualitative fecal fat.    
Management based on pathogenesis of chronic 
diarrhea  
The principles of management are accurate 
diagnosis and treatment of the specific factors that 
are causing the chronic diarrhea. Dehydration and 
severe electrolyte abnormalities are uncommon in 
patients with chronic watery diarrhea, but, when 
they occur, should be addressed with oral 
rehydration therapy. 
Treating the factors that cause the disorder is 
more specific, such as with budesonide for 
microscopic colitis or a bile acid sequestrant for 
patients with diarrhea, and is certainly more 
intellectually satisfying. However, when that is not 
possible to direct treatment to a specific etiological 
mechanism, it is important to relieve symptoms 
with non-specific therapies that address the 
secretory and motor components of chronic 
diarrhea. Opioids are the mainstay of treatment and, 
when given in a scheduled regimen, are generally 
safe. However, a recent report found that high doses 
of loperamide can induce toxic cardiac arrhythmias 
and death.32 
Table 2:  Summary and Dosages of Drugs Used in Treatment of Chronic Watery Diarrhea. Reproduced with 
permission from ref. 30 
Drug class Agent Dose 
Opiates (μ-opiate receptor selective) 
Diphenoxylate 2.5–5 mg, 4 times/day 
Loperamide 2–4 mg, 4 times/day 
Codeine 15–60 mg, 4 times/day 
Opium tincture 2–20 drops, 4 times/day 
Morphine 2–20 mg, 4 times/day 
Eluxadoline 100 mg twice daily (μ-opioid agonist and δ-
opioid antagonist) for IBS-D 
Adrenergic α2 receptor agonist 
Clonidine 0.1–0.3 mg 3 times/day; Weekly patch 
Somatostatin analogue 
Octreotide 50–250 μg 3 times/day (subcutaneously) 
Bile acid-binding resin 
Cholestyramine 4 g daily or up to 4 times/day 
Colestipol 4 g daily or up to 4 times/day 
Colesevelam 1875 mg up to twice daily 
Fiber supplements 
Calcium polycarbophil 5–10 g daily 
Psyllium 10–20 g daily 
Soluble fiber Pectin 2 capsules before meals 
Calcium 1000 mg twice or 3 times daily 
Serotonin 5-HT3 receptor antagonists 
Alosetron 0.5-1.0 mg twice daily 
Ondansetron 2-8 mg twice daily 
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Deodorized tincture of opium and morphine 
are significantly more potent, but should not be 
prescribed for the indication of chronic watery 
diarrhea.  Clonidine has been used to relieve the 
autonomic neuropathy associated with diabetic 
diarrhea, but may provide only limited benefit 
because of associated orthostatic hypotension. Use 
of the trans-dermal approach for clonidine may 
result in control of diarrhea without significant 
postural hypotension.  Chronic intermittent 
antibiotics are the mainstay of treatment for well-
proven SIBO. Several antibiotics have been shown 
to be equally effective.33 Although rifaximin is 
frequently prescribed, its use is limited by its high 
cost and regulatory approval for 3 courses, each of 
2 weeks duration. Less expensive alternatives, such 
as metronidazole, doxycycline or ciprofloxacin, 
should therefore be considered. Agents that act 
intraluminally (fiber, pectin, and calcium) may be 
helpful in patients with small volume diarrheas. In 
some cases, a cocktail of agents with different 
mechanisms is required.  
These and second-line approaches to use when 
first-line treatments fail are presented in Table 2. 
 
How to Screen for Rectal Evacuation Disorders 
in Chronic Constipation 
Rectal evacuation disorders account for 
approximately one-third of patients presenting with 
constipation in gastroenterology practice.34 A recent 
population-based study showed that defecatory 
disorders are relatively common in the community, 
with the sex-adjusted incidence rate being 5-fold 
higher in women than in men.35 The most effective 
therapeutic approach to refractory constipation with 
rectal evacuation disorders is biofeedback therapy 
or pelvic floor retraining.36 To avoid laxative 
overuse in constipated patients with rectal 
evacuation disorders and to optimize treatment in 
these patients, an accurate diagnosis for rectal 
evacuation disorders is needed. Currently, the 
diagnosis for rectal evacuation disorders is based on 
anorectal manometry and evacuation tests (balloon, 
barium or MR defecography), which are not 
generally available in internal medicine or 
gastroenterology practices. Unfortunately, there is 
also considerable discordance among tests used for 
the diagnosis of rectal evacuation disorders,37 and 
also there is lack of standardization for the balloon 
expulsion test.  
Therefore, in addition to careful clinical 
evaluation38 including digital rectal examination 
which is best for dyssynergic defecation,39 an easily 
accessible diagnostic tool with high specificity to 
select the patients with suspected rectal evacuation 
disorders is desirable prior toreferral for specialized 
tests to confirm the diagnosis. There are several 
clinical pointers in the history and examination that 
can be used, to identify dyssynergic defecation.39 A 
carefully performed digital rectal examination by a 
highly experienced expert is a good screening test, 
with 75% sensitivity and 87% specificity.39 
However, it is operator dependent and even 
gastroenterologists fail to perform the rectal 
examination for a variety of reasons.40 Therefore, 
there is need for a test that can corroborate the 
clinical impression and support referral for 
specialized anorectal testing. One test that is often 
performed to exclude other diseases in patients 
presenting with constipation is abdominal and 
pelvic computerized tomography (CT). 
In 118 patients [(102 females) who underwent 
CT abdomen and pelvis among >1500 patients with 
constipation evaluated by a single experienced 
gastroenterologist over 20 years], there were 63 
with rectal evacuation disorders, 17 with slow 
transit constipation (STC), and 38 with normal 
transit constipation (NTC), based on the sum  of the 
evidence from clinical findings and results of 
laboratory or radiological investigations.41 Using 
abdomen and pelvis CT, the rectal gas volume and 
maximal rectal gas transaxial area (MRGTA) were 
significantly greater in constipated patients with 
rectal evacuation disorders than in those without 
rectal evacuation disorders.41 Assessment of rectal 
gas area or volume on abdominal imaging may 
indicate rectal evacuation disorders in patients with 
constipation. At ~90% specificity for rectal 
evacuation disorders, the rectal gas volume of 20 or 
30mL or MRGTA of 10cm2 on CT have a positive 
predictive value of ~75%, and rectal area on scout 
film of >9cm2 has a positive predictive value of 
~69% [Figure 3].41  
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Figure 3:  Scout film (upper left), coronal image (upper middle) and cross-sectional image on CT (lower left) 
from a 44 year-old female with rectal evacuation disorder. The rectal gas volume was 77.5mL and maximum 
rectal gas area was 22.2cm2. Patients with rectal evacuation disorder have retention of isotope in the left colon 
at 24 and 48h (lower middle). Data for the three groups (upper right) are summarized and show higher RGV in 
patients with RED compared to NTC and STC. ROC curves (lower right) of rectal gas volume, maximal rectal 
gas area, and area of rectal gas (vertical) on the 2-dimensional abdominal film (scout) to identify a rectal 
evacuation disorder.  Note the two approaches have similar performance characteristics. Reproduced with 
permission from ref. 41. 
RGV, rectal gas volume; MRGTA, maximum rectal gas transaxial area; RGA on scout, area of rectal gas on 
the 2-dimensional abdominal film (scout) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypotheses on the Etiology of Infantile Colic 
Infantile colic is a syndrome characterized by 
recurrent irritability and inconsolable crying and 
screaming, accompanied by clenched fists, drawn-
up legs, and a red face. It usually starts in the 
second or third week after birth, and peaks at 5 to 8 
weeks of age. It generally stops spontaneously by 4 
months of age. The prevalence is estimated to be 
between 5% and 28%.42 A recent review identified 
three hypotheses for the etiology of infantile colic. 
First, immaturity of hepatic synthesis, reduced 
intraluminal levels of bile acids, and impaired ileal 
absorption of bile acids in the neonate result in 
malabsorption of fat and other nutrients, with 
potential for secondary effects on colonic microbial 
flora. A second hypothesis proposes that the colonic 
microbial flora are abnormal and result in increased 
nutrient fermentation and reduced levels of 
dehydroxylated bile acids in the colon. Third, 
immaturity of the enteric nervous system (ENS) 
may lead to abnormal motor and sensory functions 
of the intestine and colon.43 Given the reversal of 
symptoms by 4 months of age, the concept that 
colic results from a dysmaturity of one of these 
digestive processes seems compelling.   
Overall, the literature provides evidence for 
interaction among these three mechanisms. 
Understanding these potential mechanisms may 
lead to the introduction of diagnostic procedures 
that should enhance the selection or 
individualization of therapy for infantile colic. 
 
Lessons from an Esoteric Motility Disorder 
The most recognized gastrointestinal motility 
disorders presenting in neonates or infancy are 
congenital hypertrophic pyloric stenosis (which is 
easily managed by surgical pyloromyotomy and has 
undergone limited investigation of the genetic 
mechanisms) or Hirschsprung’s disease which is 
associated with several genetic abnormalities in Ret 
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kinase, endothelin B and its receptor, and SOX10 
pathways.   
On the other hand, multiple endocrine 
neoplasia type 2B (MEN2B) is an autosomal 
dominant syndrome caused by germline activating 
mutations of the RET proto-oncogene (typically at 
the M918T locus).  It is associated in all patients 
with medullary thyroid cancer, and mucosal 
neuromas, and less frequently with 
phaeochromocytoma.  Ganglioneuromas associated 
with megacolon are characterized by an increased 
number of ganglion cells and nerve fibers in all 
layers of the bowel wall.44 The ganglioneuromas 
can lead to loss of bowel tone, distension, 
segmental dilation and, ultimately, megacolon. 
Megacolon is characterized on imaging 
studies by a permanently enlarged colon diameter 
which is greater than 6.5 cm at pelvic brim, greater 
than 8 cm in the ascending colon, or greater than 12 
cm in the cecum.45 Infants with MEN2B frequently 
experience gastrointestinal symptoms,46 with 
constipation and intermittent diarrhea being the 
most frequently reported.47 Sixty percent of patients 
have prominent lips and 100% of patients have 
neurofibromas on their tongue, particularly the 
anterior two-thirds of the tongue. This physical 
finding should be sought, and plain abdominal 
radiograph should be conducted in patients 
presenting with abdominal pain, constipation, 
bloating and distension, as they may identify 
megacolon or rectal evacuation disorders (see 
above) which may be mistaken for chronic 
functional gastrointestinal disorders and yet could 
be eminently treatable by laparoscopic colectomy or 
retraining of the pelvic floor respectively. Indeed, 5 
of 7 recently reported patients with megacolon 
associated with MEN2B underwent colectomy with 
excellent outcomes.48 Among these 7 patients with 
megacolon and MEN2B, 2 patients also had 
esophageal achalasia and 1 had a Zenker’s 
diverticulum; therefore, patients should be screened 
for esophageal dysmotility and treated according to 
the diagnosis.  
Conclusion 
There have been significant advances in the 
understanding of motility and functional lower 
gastrointestinal disorders that augur well for 
optimizing management of patients with these 
conditions. Perhaps, it is most important to 
recognize that understanding the mechanisms has 
moved these from idiopathic or cryptogenic 
disorders to organic diseases and has changed the 
attitude of health care providers to empathize with 
the suffering and legitimate pleas of millions of 
patients for effective therapies. 
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